Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021077215 - DENDRITIC CELL-TARGETING UNIVERSAL VACCINE FOR INFLUENZA INFECTION

Publication Number WO/2021/077215
Publication Date 29.04.2021
International Application No. PCT/CA2020/051409
International Filing Date 21.10.2020
IPC
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
A61K 39/145 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
A61K 39/295 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
A61P 31/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
A61P 37/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C07K 14/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
CPC
A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens
A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C07K 14/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
C07K 14/11
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
Applicants
  • UNIVERSITY OF MANITOBA [CA]/[CA]
Inventors
  • YAO, Xiao-Jian
Agents
  • ADE & COMPANY INC.
Priority Data
62/923,84221.10.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DENDRITIC CELL-TARGETING UNIVERSAL VACCINE FOR INFLUENZA INFECTION
(FR) VACCIN UNIVERSEL CIBLANT DES CELLULES DENDRITIQUES POUR INFECTION GRIPPALE
Abstract
(EN)
We have recently developed a novel DC-targeting vaccine platform using Ebola glycoprotein (EboGP) DC-targeting domain-based fusion protein technology. Here, we will use this technology to generate universal vaccines against Influenza A by fusing a DC-targeting/activation domain (EboGPAM), derived from EboGP to I) a tetrameric conserved extracellular domain of M2 (M2e) of Influenza A strains from human, birds, and swine; 2) the conserved stalk regions (HAcs) of HA and an M2 polypeptide from H5N1 strain; and 3) the HA head regions polypeptides (HAH5-1-3) derived from H5N1, H1 N1 and H3N2 strains.
(FR)
Nous avons récemment développé une nouvelle plate-forme de vaccin ciblant des DC à l'aide d'une technologie de protéine de fusion à base de domaine ciblant DC de glycoprotéine d'Ebola (EboGP). Dans la présente invention, nous utiliserons cette technologie pour générer des vaccins universels contre la grippe A par fusion d'un domaine de ciblage/activation de DC (EboGPAM), dérivé de EboGP à I) un domaine extracellulaire conservé tétramère de M2 (M2e) de souches de grippe A provenant d'êtres humains, d'oiseaux et de porcs; 2) de régions tiges conservées (HAc) de HA et un polypeptide M2 de la souche H5N1; et 3) les polypeptides des régions têtes HA (HAH5-1-3) dérivés de souches H5N1, H1 N1 et H3N2.
Latest bibliographic data on file with the International Bureau